title: Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases.
abstract: Insufficient blood flow within colo-rectal hepatic metastases is a factor which may limit drug delivery to, and thus the response of, these tumours to regional chemotherapy. Loco-regional flow may be manipulated pharmacologically to enhance the tumour blood flow relative to that of the normal liver. However, as yet, only transient effects have been studied. Patients receiving regional chemotherapy for unresectable hepatic disease were given a 45 min regional infusion of the vasoconstrictor Angiotensin II. Intrahepatic blood flow distribution was assessed serially by Positron Emission Tomography (PET) imaging together with the trapping tracer copper(II) pyruvaldehyde bis(N-4-methylthiosemicarbazone) (Cu-PTSM) labelled using copper-62. Eleven lesions in nine patients were studied, with no adverse effects. Prior to Angiotensin II administration tumour blood flow was generally found to be greater than that of liver (10/11 lesions; 8/9 patients; median TNR 1.3, iqr 0.9-2.5). A significant increase in relative flow to tumour was seen in response to 10 min Angiotensin II infusion in most cases (7/11 lesions; 7/9 patients; median TNR 2.1, iqr 1.4-4.1; P = 0.008), which appeared to be sustained throughout the 45 min infusion period (median TNR 1.85, iqr 1.3-3.8; P = 0.03). These effects were accompanied by transient elevation of mean arterial pressure, but no change in pulse rate. These observations suggest that prolonged regional vasoconstrictor administration could prove useful in the management of unresectable colo-rectal hepatic metastases, and that further development of vascular manipulation to enhance tumour targeting and drug delivery is warranted.
authors.affiliation: Department of Gastrointestinal Surgery, Imperial College School of Medicine, Chelsea, UK.
authors.forename: D
authors.initials: D
authors.lastname: Burke
authors.forename: M M
authors.initials: MM
authors.lastname: Davies
authors.forename: J
authors.initials: J
authors.lastname: Zweit
authors.forename: M A
authors.initials: MA
authors.lastname: Flower
authors.forename: R J
authors.initials: RJ
authors.lastname: Ott
authors.forename: M J
authors.initials: MJ
authors.lastname: Dworkin
authors.forename: C
authors.initials: C
authors.lastname: Glover
authors.forename: V R
authors.initials: VR
authors.lastname: McCready
authors.forename: P
authors.initials: P
authors.lastname: Carnochan
authors.forename: T G
authors.initials: TG
authors.lastname: Allen-Mersh
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000503:physiopathology; D003301:Copper Radioisotopes; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D013882:Thiosemicarbazones / Q000493:pharmacokinetics; D013997:Time Factors; D014055:Tomography, Emission-Computed; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
chemical_list: D003301:Copper Radioisotopes; D009942:Organometallic Compounds; D013882:Thiosemicarbazones; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; C052629:copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex